Literature DB >> 17701431

The anti-cancer effects of quinolone antibiotics?

M Paul1, A Gafter-Gvili, A Fraser, L Leibovici.   

Abstract

A previous meta-analysis showed that quinolones administered for prophylaxis of infections among cancer patients reduced all-cause mortality. We extracted from the primary trials infection-related and all-cause mortality as reported and assessed the effect of quinolones on non-infection-related mortality through meta-analysis. Among trials comparing quinolones to placebo or no treatment, a significant reduction in non-infection-related mortality was observed (relative risk 0.54, 95% confidence interval 0.32-0.93, 15 trials, 3,320 patients). This finding might represent biased attribution of deaths to infection or might be compatible with an anti-cancer effect of quinolone antibiotics. We present further analyses addressing these possibilities.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17701431     DOI: 10.1007/s10096-007-0375-4

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  40 in total

1.  Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients.

Authors:  Anat Gafter-Gvili; Abigail Fraser; Mical Paul; Leonard Leibovici
Journal:  Ann Intern Med       Date:  2005-06-21       Impact factor: 25.391

2.  Effect of ciprofloxacin on the proliferation of osteoblast-like MG-63 human osteosarcoma cells in vitro.

Authors:  T Miclau; M L Edin; G E Lester; R W Lindsey; L E Dahners
Journal:  J Orthop Res       Date:  1998-07       Impact factor: 3.494

3.  Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line.

Authors:  O Aranha; D P Wood; F H Sarkar
Journal:  Clin Cancer Res       Date:  2000-03       Impact factor: 12.531

4.  The cytotoxic effect of fleroxacin and ciprofloxacin on transitional cell carcinoma in vitro.

Authors:  S Ebisuno; T Inagaki; Y Kohjimoto; T Ohkawa
Journal:  Cancer       Date:  1997-12-15       Impact factor: 6.860

5.  Enhanced antitumor activity of ultrasonic irradiation in the presence of new quinolone antibiotics in vitro.

Authors:  Deqing Huang; Kyoji Okada; Chiyo Komori; Eiji Itoi; Toshio Suzuki
Journal:  Cancer Sci       Date:  2004-10       Impact factor: 6.716

6.  Enhanced hematopoiesis in sublethally irradiated mice treated with various quinolones.

Authors:  I Shalit; Y Kletter; K Weiss; T Gruss; I Fabian
Journal:  Eur J Haematol       Date:  1997-02       Impact factor: 2.997

7.  Regression of rectal mucosa-associated lymphoid tissue lymphoma but persistence of Helicobacter pylori infection of gastric mucosa after administration of levofloxacin: report of a case.

Authors:  Kenji Dohden; Yasuharu Kaizaki; Osamu Hosokawa; Hiroyuki Hayashi; Masakazu Hattori
Journal:  Dis Colon Rectum       Date:  2004-08-19       Impact factor: 4.585

8.  Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial.

Authors:  J E Karp; W G Merz; C Hendricksen; B Laughon; T Redden; B J Bamberger; J G Bartlett; R Saral; P J Burke
Journal:  Ann Intern Med       Date:  1987-01       Impact factor: 25.391

Review 9.  Immunomodulatory effects of quinolones.

Authors:  Axel Dalhoff; Itamar Shalit
Journal:  Lancet Infect Dis       Date:  2003-06       Impact factor: 25.071

Review 10.  Immunomodulatory activities of fluoroquinolones.

Authors:  A Dalhoff
Journal:  Infection       Date:  2005-12       Impact factor: 3.553

View more
  8 in total

Review 1.  Using human experience to identify drug repurposing opportunities: theory and practice.

Authors:  D Cavalla
Journal:  Br J Clin Pharmacol       Date:  2019-02-03       Impact factor: 4.335

2.  Gemifloxacin inhibits migration and invasion and induces mesenchymal-epithelial transition in human breast adenocarcinoma cells.

Authors:  Tun-Chieh Chen; Ya-Ling Hsu; Yu-Chieh Tsai; Yu-Wei Chang; Po-Lin Kuo; Yen-Hsu Chen
Journal:  J Mol Med (Berl)       Date:  2013-09-05       Impact factor: 4.599

3.  Targeting the transposase domain of the DNA repair component Metnase to enhance chemotherapy.

Authors:  Elizabeth A Williamson; Leah Damiani; Andrei Leitao; Chelin Hu; Helen Hathaway; Tudor Oprea; Larry Sklar; Montaser Shaheen; Julie Bauman; Wei Wang; Jac A Nickoloff; Suk-Hee Lee; Robert Hromas
Journal:  Cancer Res       Date:  2012-10-22       Impact factor: 12.701

4.  Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells.

Authors:  Ella L Kim; Robin Wüstenberg; Anne Rübsam; Christoph Schmitz-Salue; Gabriele Warnecke; Eva-Maria Bücker; Nadine Pettkus; Daniel Speidel; Veit Rohde; Walter Schulz-Schaeffer; Wolfgang Deppert; Alf Giese
Journal:  Neuro Oncol       Date:  2010-01-27       Impact factor: 12.300

5.  Tumour cell population growth inhibition and cell death induction of functionalized 6-aminoquinolone derivatives.

Authors:  G Franci; G Manfroni; R Cannalire; T Felicetti; O Tabarrini; A Salvato; M L Barreca; L Altucci; V Cecchetti
Journal:  Cell Prolif       Date:  2015-12       Impact factor: 6.831

6.  Upregulation of wild-type p53 by small molecule-induced elevation of NQO1 in non-small cell lung cancer cells.

Authors:  Hong Yu; Hong-Ying Gao; Hua Guo; Gui-Zhen Wang; Yi-Qing Yang; Qian Hu; Li-Jun Liang; Qun Zhao; Da-Wei Xie; Yu Rao; Guang-Biao Zhou
Journal:  Acta Pharmacol Sin       Date:  2021-05-25       Impact factor: 6.150

Review 7.  Selective toxicity of antibacterial agents-still a valid concept or do we miss chances and ignore risks?

Authors:  Axel Dalhoff
Journal:  Infection       Date:  2020-12-23       Impact factor: 7.455

8.  Anti-Proliferative and Pro-Apoptotic Activities of Synthesized 3,4,5 Tri-Methoxy Ciprofloxacin Chalcone Hybrid, through p53 Up-Regulation in HepG2 and MCF7 Cell Lines.

Authors:  Marwa A Eisa; Moustafa Fathy; Gamal El-Din A A Abuo-Rahma; Mohamed Abdel-Aziz; Maiiada Hassan Nazmy
Journal:  Asian Pac J Cancer Prev       Date:  2021-10-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.